KEYNOTE Trials for Triple-Negative Breast Cancer
For high-risk early-stage TNBC, use pembrolizumab 200 mg IV every 3 weeks with neoadjuvant chemotherapy (4 cycles paclitaxel/carboplatin, then 4 cycles doxorubicin or epirubicin/cyclophosphamide), followed by 9 cycles of adjuvant pembrolizumab after surgery—this regimen from KEYNOTE-522 significantly improves overall survival. 1, 2
Early-Stage TNBC: KEYNOTE-522 Results
Patient Selection & Regimen
The KEYNOTE-522 trial enrolled patients with newly diagnosed, previously untreated high-risk early-stage TNBC defined as:
- Tumor >1 cm but ≤2 cm with nodal involvement, OR
- Tumor >2 cm regardless of nodal status
- No PD-L1 testing required 1, 2
Treatment Protocol
Neoadjuvant Phase:
- Pembrolizumab 200 mg IV every 3 weeks × 4 cycles PLUS:
- Paclitaxel 80 mg/m² weekly (Days 1,8,15)
- Carboplatin AUC 5 every 3 weeks OR AUC 1.5 weekly
- Followed by pembrolizumab 200 mg IV every 3 weeks × 4 cycles PLUS:
- Doxorubicin 60 mg/m² OR epirubicin 90 mg/m² every 3 weeks
- Cyclophosphamide 600 mg/m² every 3 weeks
Adjuvant Phase (post-surgery):
Efficacy Outcomes
At 75.1 months median follow-up:
- Overall survival at 60 months: 86.6% with pembrolizumab-chemotherapy vs 81.7% with chemotherapy alone (HR 0.69; P=0.002) 2
- Event-free survival at 36 months: 84.5% vs 76.8% (HR 0.63; P<0.001) 3
- Pathological complete response: 64.8% vs 51.2% 1
Critical finding: Pembrolizumab benefit extends beyond achieving pCR—patients with residual disease (RCB-2) showed the greatest EFS benefit (HR 0.52), demonstrating that adjuvant pembrolizumab provides additional protection even without complete pathologic response 4
Guideline Recommendations
Both NCCN and ESMO strongly endorse this approach:
- NCCN: If pembrolizumab was given with neoadjuvant chemotherapy, continue adjuvant pembrolizumab based on KEYNOTE-522 data 5
- ESMO: For cT2-4 N0 or any N-positive (stage II-III) TNBC, use neoadjuvant chemotherapy plus pembrolizumab unless contraindications exist. Continue pembrolizumab for 9 cycles adjuvantly regardless of pCR status [I, A recommendation] 6
Safety Considerations
Do not use pembrolizumab if:
- Active autoimmune disease requiring systemic therapy within 2 years
- Medical condition requiring immunosuppression 1
Monitor closely for immune-related adverse events throughout treatment and follow ESMO guidelines for toxicity management 6. Grade 3-5 treatment-related adverse events occurred in 68% of patients, with <1% treatment-related deaths 1
Metastatic TNBC: KEYNOTE-355 Results
Patient Selection
Requires PD-L1 testing: Only use pembrolizumab in metastatic TNBC with PD-L1 CPS ≥10 1
Treatment Regimen
Pembrolizumab 200 mg IV every 3 weeks PLUS one of:
- Nab-paclitaxel
- Paclitaxel
- Gemcitabine plus carboplatin 7
Efficacy by PD-L1 Status
At 25.9 months median follow-up:
- CPS ≥10: Median PFS 9.7 months vs 5.6 months (HR 0.65; P=0.0012) ✓ Met primary endpoint
- CPS ≥1: Median PFS 7.6 months vs 5.6 months (HR 0.74; P=0.0014) ✗ Did not meet significance threshold
- All patients: Median PFS 7.5 months vs 5.6 months (HR 0.82; not tested) 7
The treatment effect clearly increases with PD-L1 enrichment—this is why FDA approval requires CPS ≥10 1
Guideline Alignment
FDA label explicitly states: "KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10)" 1
KEYNOTE-119: Monotherapy in Previously Treated Metastatic TNBC
Pembrolizumab monotherapy failed to improve overall survival in second-line or third-line metastatic TNBC compared to chemotherapy, even in PD-L1-enriched populations 8. This trial enrolled patients who received 1-2 prior lines for metastatic disease.
Key negative results:
- CPS ≥10: Median OS 12.7 vs 11.6 months (HR 0.78; P=0.057) ✗ Not significant
- CPS ≥1: Median OS 10.7 vs 10.2 months (HR 0.86; P=0.073) ✗ Not significant
- All patients: Median OS 9.9 vs 10.8 months (HR 0.97) 8
Clinical implication: Do not use pembrolizumab monotherapy for metastatic TNBC—combination with chemotherapy is required for benefit.
Sequencing with Other Agents
With Capecitabine (Residual Disease After Neoadjuvant)
For patients with TNBC and residual disease after preoperative therapy who did NOT receive pembrolizumab:
- Adjuvant capecitabine improves DFS (HR 0.70) and OS (HR 0.52 in TNBC) 5
- No data exist on combining or sequencing capecitabine with pembrolizumab—patients in KEYNOTE-522 did not receive capecitabine 5
- ESMO states combination "may be considered on an individual basis" but provides no strong recommendation 6
With Olaparib (gBRCA1/2 Mutations)
For germline BRCA1/2-mutated TNBC with residual disease or high-risk features:
- Olaparib for 1 year is category 1 recommendation 5
- No data on sequencing with pembrolizumab—OlympiA trial excluded patients who received ICIs 5
- ESMO suggests combination "may be considered on an individual basis" 6
Practical approach: If patient received pembrolizumab neoadjuvantly with residual disease AND has gBRCA mutation, prioritize completing adjuvant pembrolizumab first (stronger OS data), then consider olaparib if additional risk reduction desired.
Common Pitfalls to Avoid
Do not give pembrolizumab solely in adjuvant setting without prior neoadjuvant ICI treatment—no evidence supports this 6
Do not use pembrolizumab monotherapy for metastatic TNBC—KEYNOTE-119 showed no benefit 8
Do not skip PD-L1 testing in metastatic setting—only CPS ≥10 benefits from pembrolizumab addition 1, 7
Do not stop adjuvant pembrolizumab based on pCR status—KEYNOTE-522 showed benefit regardless of pathologic response, with RCB-2 patients deriving substantial EFS benefit 4
Do not use in patients with active autoimmune disease or those requiring immunosuppression 1